OptimizeRx (OPRX) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.

7 analysts have issued 12-month target prices for OptimizeRx's shares. Their OPRX share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 49.6% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.

OptimizeRx's stock was trading at $16.80 at the start of the year. Since then, OPRX shares have decreased by 16.4% and is now trading at $14.04.
View the best growth stocks for 2023 here.

OptimizeRx saw a decline in short interest in May. As of May 15th, there was short interest totaling 710,500 shares, a decline of 19.7% from the April 30th total of 884,500 shares. Based on an average daily trading volume, of 250,800 shares, the days-to-cover ratio is presently 2.8 days. Approximately 4.3% of the shares of the stock are sold short.
View OptimizeRx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OPRX earnings forecast.

OptimizeRx Co. (NASDAQ:OPRX) issued its earnings results on Wednesday, March, 8th. The company reported $0.01 EPS for the quarter. The firm had revenue of $19.70 million for the quarter, compared to analysts' expectations of $21.84 million. OptimizeRx had a negative net margin of 22.79% and a negative trailing twelve-month return on equity of 9.27%.

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD), Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC),

OptimizeRx updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $68.69M-, compared to the consensus revenue estimate of $68.64 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.08%), First Light Asset Management LLC (5.90%), Blair William & Co. IL (4.93%), G2 Investment Partners Management LLC (3.13%), Wasatch Advisors LP (2.74%) and State Street Corp (2.47%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPRX stock can currently be purchased for approximately $14.04.

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $240.51 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.